QT Vascular's Q2 loss widens on expenses

BALLOONING administrative and research and development expenses caused Catalist-listed QT Vascular's net loss for the quarter ended June to widen, from US$11.4 million to US$13.5 million even as revenue tripled. For the second quarter, revenue rose from US$1.03 million to US$3.23 million.

The increase...

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to